Tesamorelin dosage calculator: how to work out your dose

Last updated 2026-07-24

what does a tesamorelin dosage calculator actually calculate?

Almost every tool marketed as a "tesamorelin dosage calculator" is really doing one job: converting a vial's total peptide content and diluent volume into a per-injection number of milliliters or units on an insulin syringe. It is not calculating what your dose should be. That part is fixed by the FDA label for the approved product and otherwise set by a prescriber. The approved drug, tesamorelin for injection (brand name Egrifta, and the later Egrifta SV formulation), carries a single approved adult dose: 2 mg injected subcutaneously once daily ^[1][2]. There is no FDA-approved sliding scale by body weight, sex, or fat mass. The phase 3 trials that support approval tested 2 mg/day against placebo in adults with HIV-associated lipodystrophy and excess abdominal fat, not a range of doses titrated per patient ^[3]. So a calculator that asks for your weight and spits out a personalized milligram dose is inventing a formula that doesn't exist in the approved prescribing information. What a reconstitution calculator can legitimately do is arithmetic: given a 1 mg or 2 mg vial and a stated amount of bacteriostatic water, tell you how many mL correspond to a 2 mg dose, or to whatever dose your prescriber has written on the label. That's a genuinely useful, low-risk calculation. Confusing it with dose-finding is where people get into trouble.

what is the fda-approved tesamorelin dose (and what isn't approved)?

The approved dose is 2 mg by subcutaneous injection once daily, reconstituted and injected into the abdomen, for adults with HIV-associated lipodystrophy who have excess visceral abdominal fat ^[1][3]. That's the entire approved use case. It is narrow by design. The key phase 3 program pooled two multicenter, double-blind, placebo-controlled trials with safety extension data specifically in HIV patients with excess abdominal fat, and that pooled analysis is what the approval rests on ^[3]. A related dosing question the trials answered: does it matter if a patient also has a fat pad at the back of the neck (dorsocervical fat)? A post hoc analysis of the phase 3 placebo-controlled trial looked at outcomes with and without dorsocervical fat at baseline and found the drug's effect on visceral fat held regardless of that finding, though patients differed in other body composition measures ^[4]. That's a subgroup analysis within the approved population, not a different dosing rule. Everything else, meaning use in people without HIV, use for general fat loss, use for anti-aging or GH support in otherwise healthy adults, is off-label. Off-label use is legal for a prescriber to recommend under their clinical judgment, but it means the 2 mg number and the safety data behind it come from a population and context that may not match yours. For the general dosing rules and how prescribers actually titrate around the label dose, see tesamorelin dosage.

how does a tesamorelin reconstitution calculator work?

Reconstitution math has three inputs: the total peptide in the vial (commonly 1 mg or 2 mg for compounded or brand product), the volume of bacteriostatic water you add, and the dose you're drawing up. The output is how many mL, or how many units on a standard U-100 insulin syringe, deliver that dose. A worked example: if a vial holds 2 mg of tesamorelin and you reconstitute it with 2 mL of bacteriostatic water, the resulting concentration is 1 mg/mL. A 2 mg daily dose would then require drawing up the full 2 mL, which is impractical for a subcutaneous injection in one shot for many people, so many protocols reconstitute with less diluent to concentrate the dose, or split administration. If instead you reconstitute that same 2 mg vial with 1 mL, you get 2 mg/mL, meaning a full 2 mg dose is just 1 mL, or 100 units on an insulin syringe. Here's a simple reference table for common reconstitution volumes on a 2 mg vial: | Bacteriostatic water added | Resulting concentration | Volume for a 2 mg dose | Units on U-100 syringe |

is there a different tesamorelin dosage calculator for weight loss?

No validated one exists, and that's worth being blunt about. Tesamorelin is not an FDA-approved weight loss drug. The approved indication is reduction of excess visceral abdominal fat specifically in adults with HIV-associated lipodystrophy ^[1][3]. Searches for a "tesamorelin dosage calculator for weight loss" or a "tesamorelin dosage calculator for weight loss pdf" reflect real demand, but there's no dosing schedule backed by phase 3 data for general weight loss in people without HIV. What the trial evidence does show, within its actual population, is a fat quality and fat quantity effect. One study found tesamorelin improved fat quality (reducing markers linked to metabolically harmful fat) independent of changes in fat quantity, suggesting the drug does more than just shrink fat depots ^[5]. Separately, a meta-analysis of randomized controlled trials pooling body composition, hepatic fat, and metabolic outcomes in HIV-associated lipodystrophy found consistent reductions in visceral adipose tissue and liver fat markers alongside a defined safety profile, again in the approved population ^[6]. If your interest is weight loss generally, the honest answer is that tesamorelin was never tested as a weight loss drug in trials and doesn't have a weight-based dosing table because researchers didn't build one; the 2 mg/day dose in the phase 3 trials was fixed, not scaled to body weight or starting BMI ^[3]. Anyone selling a weight-based tesamorelin calculator for that purpose is extrapolating beyond the data.

does the tesamorelin dose differ for men vs. women?

A "tesamorelin dosage calculator male" and a "tesamorelin dosage calculator for weight loss female" search both reflect a reasonable question: does sex change the number. The approved label dose, 2 mg/day subcutaneously, is not split by sex ^[1]. The phase 3 trials enrolled both men and women with HIV-associated lipodystrophy and the pooled analysis that supports the approval did not establish a separate sex-based dosing regimen ^[3]. What can differ by sex, and by individual physiology more broadly, is pharmacokinetics, meaning how the drug is absorbed, distributed, and cleared. A population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects modeled exposure across a range of patient characteristics and is the kind of study that would flag a meaningful sex-driven dosing difference if one existed at a magnitude worth acting on ^[7]. That paper is about drug exposure modeling, not a revised dosing table, and it doesn't hand clinicians a male versus female dose. The practical takeaway: sex isn't a factor in the current approved dose. If a calculator claims otherwise, ask what study it's citing. If it can't name one, it's guessing.

what happens if you miss a dose or want to adjust it yourself?

The trials that support approval used a fixed, once-daily 2 mg regimen, not an as-needed or self-titrated one ^[3]. Missing an occasional dose in real-world use is common with any daily injectable, but there's no published trial arm testing intermittent dosing, double-dosing to catch up, or self-adjusted escalation, so there's no safety data behind those choices. A prescriber managing your treatment will typically tell you to simply resume the normal schedule rather than compensate with an extra dose. That's standard practice for once-daily GHRH analogues generally, though it's a clinical judgment call rather than a tested protocol specific to missed tesamorelin doses. Self-adjusting the dose upward, on the theory that more GH stimulation means faster fat loss, isn't supported by the phase 3 data, which tested only the 2 mg dose against placebo ^[3]. Higher, untested doses carry an unknown safety and efficacy profile. If your results feel slow, that's a conversation for a follow-up with your prescriber and possibly a body composition recheck, not a reason to freelance the dose.

how long does it take to see results at the approved dose?

The phase 3 program measured visceral adipose tissue by CT scan over defined trial periods, and the pooled phase 3 analysis with safety extension data is the basis for the approved efficacy claim ^[3]. Separately, a study on liver enzymes found that visceral fat reduction with tesamorelin was associated with improved liver enzyme markers in HIV, tying the visceral fat effect to a downstream metabolic benefit in that population ^[8]. A related randomized, double-blind, multicenter trial specifically examined tesamorelin's effect on non-alcoholic fatty liver disease markers in HIV and reported measurable effects on liver fat, again over a defined treatment period in that trial population ^[9]. None of these describe a week-by-week timeline you should expect on a home calculator. Body composition changes on CT or MRI take months to show up reliably, and the studies behind the approval were structured around trial visit schedules, not day-30 or day-60 checkpoints for individual patients. If a calculator promises a specific number of weeks to see fat loss, that's a marketing estimate, not a cited trial finding. For a realistic before-and-after picture drawn from the actual trial data and imaging endpoints, see tesamorelin peptide before and after.

what side effects should a dosing calculator warn you about?

A responsible reconstitution or dosing tool should flag the known, trial-documented side effect signals, more than spit out a volume. Injection site reactions (redness, itching, mild swelling) are commonly reported with subcutaneous GHRH analogue injections generally. More specific to tesamorelin's mechanism: because it stimulates GH release, it can raise insulin-like growth factor levels and has been studied for effects on glucose handling; monitoring blood glucose is part of standard clinical follow-up on this drug class. A study on inflammatory markers found that tesamorelin's effect on inflammatory markers in HIV patients with excess abdominal fat correlated with the degree of visceral adipose reduction, suggesting the metabolic benefit and the fat loss are mechanistically linked rather than separate effects ^[10]. That's reassuring about the biology, but it doesn't replace glucose monitoring in practice. There's also a research angle worth knowing about if you're sourcing product outside a regulated pharmacy: a 2021 paper on detecting GHRH synthetic analogs describes methods developed partly for anti-doping testing, which reflects that tesamorelin and related GHRH analogues are also relevant in sports-testing contexts, more than clinical ones ^[11]. That's a signal about how seriously the compound class is treated for detection and misuse, separate from any approved medical use. For the full side effect list from labeling and trial data, see tesamorelin peptide side effects.

can you buy tesamorelin as a compounded product, and does the calculator change?

Yes, tesamorelin is available both as the FDA-approved branded product and, in some cases, as a compounded preparation from a 503A or 503B pharmacy. This distinction matters for dosing math because compounded vials may come in different total mg amounts and different recommended diluent volumes than the branded product, so a reconstitution calculator has to be set to match your specific vial, not a generic assumption. Federal law treats compounding differently depending on the pharmacy type. Traditional compounding under section 503A of the Food, Drug and Cosmetic Act is governed by 21 U.S.C. 353a ^[12], and FDA maintains bulk drug substance lists specifically for what can legally be compounded under 503A, laid out in the regulation at 21 CFR 216.23 ^[13] and the related 503B outsourcing facility list at 21 CFR 216.24 ^[14]. FDA's own guidance page on bulk drug substances used in compounding under section 503A explains how a substance gets nominated and reviewed for that list ^[15]. What this means practically: a compounded vial's labeled concentration is set by the compounding pharmacy's own formulation, not a universal FDA-approved concentration, so always use the actual number printed on that specific vial's label in any reconstitution calculation, never a number copied from an unrelated product or forum post. If you're getting product through a provider-reviewed pathway, the pharmacy will typically state the concentration and recommended reconstitution volume directly, which removes most of the guesswork.

so should you actually trust a tesamorelin dosage calculator online?

Trust it for arithmetic, not for medicine. A tesamorelin reconstitution calculator online is fine, even useful, for converting mg to mL or to insulin syringe units once you already know your prescribed dose and your vial's actual concentration. Where it becomes a problem is when it also tries to tell you what your dose should be based on your weight, sex, or goals, because that number isn't backed by the phase 3 trial design, which used a single fixed 2 mg/day dose in a specific population ^[3]. A reasonable checklist before using any calculator: does it ask for your actual vial's labeled mg content and diluent volume (good sign), or does it ask for your body weight and goals to generate a dose (red flag, since that formula doesn't exist in the approved labeling)? Does it mention that the approved indication is HIV-associated lipodystrophy specifically, or does it imply general fat loss or anti-aging use (another red flag if it doesn't distinguish)? The honest workflow: get your dose from a prescriber who has reviewed your labs and history, get the exact vial concentration from your pharmacy, and only then use a calculator to convert that into a syringe-ready volume. That's the actual value a calculator adds. Tesamorelin Co's role in that chain is pointing readers toward a provider-reviewed pathway rather than acting as the prescriber itself; the clinical decision always sits with a licensed provider and the dispensing pharmacy.

Frequently asked questions

What is the standard tesamorelin dosage calculator formula?

There isn't an FDA-recognized formula that outputs a personalized mg dose. The approved dose is a fixed 2 mg subcutaneously once daily for adults with HIV-associated lipodystrophy ^[1][3]. What people call a calculator is usually reconstitution math: vial mg content divided by diluent volume equals concentration, then dose divided by concentration equals injection volume.

How do I calculate my tesamorelin reconstitution volume?

Divide the total mg in your vial by the mL of bacteriostatic water you add to get concentration (mg/mL). Then divide your prescribed dose (mg) by that concentration to get the injection volume in mL. Example: a 2 mg vial with 1 mL of diluent gives 2 mg/mL, so a 2 mg dose equals 1 mL, or 100 units on a U-100 insulin syringe.

Is there a specific tesamorelin dosage calculator for weight loss?

No validated one exists. Tesamorelin is not FDA-approved for weight loss; the approved use is reducing visceral abdominal fat in HIV-associated lipodystrophy at a fixed 2 mg/day dose tested in phase 3 trials ^[1][3]. Any weight-loss-specific dosing chart is extrapolating beyond the trial data, which used a single fixed dose regardless of body weight.

Does the tesamorelin dose change for men versus women?

The approved label dose, 2 mg/day subcutaneously, is not split by sex ^[1]. Phase 3 trials enrolled both men and women with HIV-associated lipodystrophy under the same dosing regimen ^[3]. Population pharmacokinetic modeling has examined exposure across patient groups but hasn't produced a separate sex-based dosing table ^[7].

Is there a downloadable tesamorelin dosage calculator for weight loss PDF?

Various PDFs circulate online claiming weight-based dosing schedules, but none are backed by FDA labeling or the phase 3 trial design, which used one fixed 2 mg/day dose regardless of weight or goal ^[1][3]. Treat any downloadable dosing chart as unverified unless it cites the approved label or a specific published trial.

How much bacteriostatic water do I mix with tesamorelin?

It depends on the vial's total mg content and the target concentration your prescriber or pharmacy specifies; there's no single universal volume. A 2 mg vial mixed with 1 mL yields 2 mg/mL; mixed with 2 mL it yields 1 mg/mL. Always use the volume stated on your specific product's label, not a number from an unrelated source.

What is the FDA-approved tesamorelin dose?

2 mg injected subcutaneously once daily, approved for adults with HIV-associated lipodystrophy who have excess visceral abdominal fat ^[1][3]. This dose came from pooled phase 3, double-blind, placebo-controlled trials with safety extension data, and it is the only dose with direct trial support behind the approval.

Can I use a tesamorelin dosage calculator if I'm not being treated for HIV?

You can use the reconstitution math regardless of diagnosis, but the underlying 2 mg/day dose and its safety data come specifically from trials in HIV-associated lipodystrophy ^[1][3]. Off-label use in other populations is a prescriber's clinical decision, and no separate dosing calculator exists for non-HIV use with equivalent trial backing.

What happens if a tesamorelin dosage calculator gives me units instead of mL?

Insulin syringes are marked in units, where 100 units equals 1 mL on a standard U-100 syringe. A calculator converting your mg dose to units is doing the same math as mL, just in syringe-readable form. Confirm the syringe type matches U-100 assumptions, since other syringe markings (U-40, for example) would change the conversion.

How long before tesamorelin dosing shows visible results?

Phase 3 trials measured visceral fat by CT scan over structured, multi-month trial periods rather than tracking week-by-week visible change ^[3]. Related studies link visceral fat reduction to improved liver enzyme markers over the trial course ^[8]. No study establishes a specific number of weeks for visible results in an individual, so timelines from calculators are marketing estimates, not trial data.

Does tesamorelin dosage need to be adjusted based on liver or kidney function?

Population pharmacokinetic modeling in HIV-infected patients and healthy subjects examined how patient characteristics affect drug exposure ^[7], and this is the kind of data a prescriber uses to judge whether dose adjustment is warranted for a given patient. There's no universal self-adjustment formula; any change for organ function should come from a prescriber reviewing your labs.

Is a compounded tesamorelin vial dosed the same as the branded product?

Not necessarily. Compounded vials can differ in total mg content and recommended reconstitution volume from the branded product, so always use the specific concentration printed on your vial's label. Compounding is regulated separately under 21 U.S.C. 353a and FDA's 503A bulk drug substance rules ^[12][13], and formulations can vary by pharmacy.

Sources

1. PubMed, Tesamorelin (2012): The FDA-approved dose of tesamorelin is 2 mg subcutaneously once daily for HIV-associated lipodystrophy.
2. PubMed, Tesamorelin (Nature Reviews Drug Discovery, 2011): Tesamorelin is marketed as Egrifta, an approved GHRH analogue for HIV-associated lipodystrophy.
3. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis (J Clin Endocrinol Metab, 2010): Pooled phase 3, double-blind, placebo-controlled trials with safety extension data tested a fixed 2 mg/day dose in HIV patients with excess abdominal fat, forming the basis for approval.
4. PubMed, Effect of tesamorelin with and without dorsocervical fat: post hoc analysis (J Clin Transl Sci, 2023): A post hoc analysis of the phase 3 placebo-controlled trial examined tesamorelin's effect on visceral fat in patients with and without dorsocervical fat at baseline.
5. PubMed, Tesamorelin improves fat quality independent of changes in fat quantity (AIDS, 2021): Tesamorelin improved markers of fat quality independent of changes in fat quantity in the studied population.
6. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin: meta-analysis of RCTs (Obes Res Clin Pract, 2026): A meta-analysis of randomized controlled trials found consistent reductions in visceral adipose tissue and hepatic fat markers with tesamorelin in HIV-associated lipodystrophy.
7. PubMed, Population pharmacokinetic analysis of tesamorelin (Clin Pharmacokinet, 2015): Population pharmacokinetic modeling of tesamorelin examined drug exposure across HIV-infected patients and healthy subjects.
8. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017): Visceral fat reduction with tesamorelin correlated with improved liver enzyme markers in an HIV population.
9. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (Lancet HIV, 2019): A randomized, double-blind, multicenter trial found effects of tesamorelin on liver fat markers in HIV-associated NAFLD.
10. PubMed, Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat (AIDS, 2011): Tesamorelin's effect on inflammatory markers correlated with the degree of visceral adipose tissue reduction.
11. PubMed, Advances in the detection of growth hormone releasing hormone synthetic analogs (Drug Test Anal, 2021): Detection methods for GHRH synthetic analogs like tesamorelin have been developed partly for anti-doping testing contexts.
12. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Traditional pharmacy compounding under section 503A of the FDCA is governed by 21 U.S.C. 353a.
13. eCFR, 21 CFR 216.23: FDA maintains a bulk drug substances list specifically for what can legally be compounded under section 503A.
14. eCFR, 21 CFR 216.24: FDA maintains a separate bulk drug substances list for 503B outsourcing facilities.
15. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA explains how a bulk drug substance gets nominated and reviewed for the 503A compounding list.